Trials / Unknown
UnknownNCT04720807
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer: a Prospective, Single-arm, Open Label, Exploratory Phase 2 Clinical Trial.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.
Detailed description
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.The patient has undergone surgery and received ≥2 lines of platinum-containing chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Letrozole combined with anlotinib hydrochloride | Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer. |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2022-08-31
- Completion
- 2023-09-30
- First posted
- 2021-01-22
- Last updated
- 2021-01-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04720807. Inclusion in this directory is not an endorsement.